Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.
Based on the Rigel Pharmaceuticals Inc stock forecasts from 7 analysts, the average analyst target price for Rigel Pharmaceuticals Inc is USD 2.58 over the next 12 months. Rigel Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Rigel Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Rigel Pharmaceuticals Inc’s stock price was USD 0.72. Rigel Pharmaceuticals Inc’s stock price has changed by -56.63% over the past week, -63.45% over the past month and -82.40% over the last year.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.
Based on the Rigel Pharmaceuticals Inc stock forecasts from 5 analysts, the average analyst target price for Rigel Pharmaceuticals Inc is USD 3.25 over the next 12 months. Rigel Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Rigel Pharmaceuticals Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Rigel Pharmaceuticals Inc’s stock price was USD 0.70. Rigel Pharmaceuticals Inc’s stock price has changed by -59.77% over the past week, -68.47% over the past month and -82.46% over the last year.
Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succ...Stocktargetadvisor.com
Based on the Biogen Inc stock forecasts from 19 analysts, the average analyst target price for Biogen Inc is USD 262.33 over the next 12 months. Biogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biogen Inc is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Biogen Inc’s stock price was USD 276.61. Biogen Inc’s stock price has changed by +38.76% over the past week, +39.29% over the past month and -2.85% over the last year.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. Based on the Gilead Sciences Inc stock forecasts from 14 analysts, the average analyst target price for Gilead Sciences Inc is USD 72.48 over the next 12 months. Gilead Sciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Gilead Sciences Inc is Bullish , which is based on 12 positive signals and 5 negative signals. At the last closing, Gilead Sciences Inc’s stock price was USD 62.37. Gilead Sciences Inc’s stock price has changed by +1.95% over the past week, +0.89% over the past month and -8.99% over the last year.
Based on the Prothena Corporation plc stock forecasts from 4 analysts, the average analyst target price for Prothena Corporation plc is USD 62.00 over the next 12 months. Prothena Corporation plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Prothena Corporation plc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Prothena Corporation plc’s stock price was USD 58.00. Prothena Corporation plc’s stock price has changed by +85.24% over the past week, +107.29% over the past month and -19.21% over the last year.
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products.
Based on the Canopy Growth Corporation stock forecasts from 15 analysts, the average analyst target price for Canopy Growth Corporation is USD 8.23 over the next 12 months. Canopy Growth Corporation’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Canopy Growth Corporation is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Canopy Growth Corporation’s stock price was USD 4.97. Canopy Growth Corporation’s stock price has changed by +4.41% over the past week, -12.96% over the past month and -80.95% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 11 analysts, the average analyst target price for Moderna Inc is USD 188.39 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 145.34. Moderna Inc’s stock price has changed by +0.01% over the past week, +8.14% over the past month and -33.81% over the last year.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap.
Based on the Aldeyra The stock forecasts from 5 analysts, the average analyst target price for Aldeyra The is USD 19.67 over the next 12 months. Aldeyra The’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aldeyra The is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aldeyra The’s stock price was USD 3.86. Aldeyra The’s stock price has changed by +26.14% over the past week, +56.28% over the past month and -69.29% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.
Based on the Rigel Pharmaceuticals Inc stock forecasts from 5 analysts, the average analyst target price for Rigel Pharmaceuticals Inc is USD 3.25 over the next 12 months. Rigel Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Rigel Pharmaceuticals Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Rigel Pharmaceuticals Inc’s stock price was USD 0.70. Rigel Pharmaceuticals Inc’s stock price has changed by -59.77% over the past week, -68.47% over the past month and -82.46% over the last year.
Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succ...Stocktargetadvisor.com
Based on the Biogen Inc stock forecasts from 19 analysts, the average analyst target price for Biogen Inc is USD 262.33 over the next 12 months. Biogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biogen Inc is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Biogen Inc’s stock price was USD 276.61. Biogen Inc’s stock price has changed by +38.76% over the past week, +39.29% over the past month and -2.85% over the last year.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. Based on the Gilead Sciences Inc stock forecasts from 14 analysts, the average analyst target price for Gilead Sciences Inc is USD 72.48 over the next 12 months. Gilead Sciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Gilead Sciences Inc is Bullish , which is based on 12 positive signals and 5 negative signals. At the last closing, Gilead Sciences Inc’s stock price was USD 62.37. Gilead Sciences Inc’s stock price has changed by +1.95% over the past week, +0.89% over the past month and -8.99% over the last year.
Based on the Prothena Corporation plc stock forecasts from 4 analysts, the average analyst target price for Prothena Corporation plc is USD 62.00 over the next 12 months. Prothena Corporation plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Prothena Corporation plc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Prothena Corporation plc’s stock price was USD 58.00. Prothena Corporation plc’s stock price has changed by +85.24% over the past week, +107.29% over the past month and -19.21% over the last year.
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products.
Based on the Canopy Growth Corporation stock forecasts from 15 analysts, the average analyst target price for Canopy Growth Corporation is USD 8.23 over the next 12 months. Canopy Growth Corporation’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Canopy Growth Corporation is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Canopy Growth Corporation’s stock price was USD 4.97. Canopy Growth Corporation’s stock price has changed by +4.41% over the past week, -12.96% over the past month and -80.95% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 11 analysts, the average analyst target price for Moderna Inc is USD 188.39 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 145.34. Moderna Inc’s stock price has changed by +0.01% over the past week, +8.14% over the past month and -33.81% over the last year.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap.
Based on the Aldeyra The stock forecasts from 5 analysts, the average analyst target price for Aldeyra The is USD 19.67 over the next 12 months. Aldeyra The’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aldeyra The is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aldeyra The’s stock price was USD 3.86. Aldeyra The’s stock price has changed by +26.14% over the past week, +56.28% over the past month and -69.29% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 11 analysts, the average analyst target price for Moderna Inc is USD 184.76 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 121.08. Moderna Inc’s stock price has changed by -9.67% over the past week, -11.14% over the past month and -38.80% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 12 analysts, the average analyst target price for Moderna Inc is USD 195.35 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 140.00. Moderna Inc’s stock price has changed by -5.19% over the past week, +4.17% over the past month and -32.06% over the last year.
MRNA Stock Forecast & Price:
Based on the Moderna Inc stock forecast from 7 analysts, the average analyst target price for Moderna Inc is USD 147.44 over the next 12 months. Moderna Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Moderna Inc’s stock price was USD 123.42. Moderna Inc’s stock price has changed by +2.01% over the past week, -13.26% over the past month and -59.52% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 12 analysts, the average analyst target price for Moderna Inc is USD 195.35 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 143.40. Moderna Inc’s stock price has changed by +9.59% over the past week, +6.69% over the past month and -22.34% over the last year.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs).
Based on the IVERIC bio Inc stock forecasts from 9 analysts, the average analyst target price for IVERIC bio Inc is USD 23.22 over the next 12 months. IVERIC bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of IVERIC bio Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, IVERIC bio Inc’s stock price was USD 11.25. IVERIC bio Inc’s stock price has changed by +8.91% over the past week, -9.35% over the past month and +70.45% over the last year.
Based on the Moderna Inc stock forecasts from 7 analysts, the average analyst target price for Moderna Inc is USD 147.44 over the next 12 months. Moderna Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Moderna Inc’s stock price was USD 118.07. Moderna Inc’s stock price has changed by -5.03% over the past week, -13.98% over the past month and -68.84% over the last year.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
Based on the Bristol-Myers Squibb Company stock forecasts from 9 analysts, the average analyst target price for Bristol-Myers Squibb Company is USD 73.91 over the next 12 months. Bristol-Myers Squibb Company’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bristol-Myers Squibb Company is Slightly Bearish, which is based on 6 positive signals and 9 negative signals. At the last closing, Bristol-Myers Squibb Company’s stock price was USD 75.09. Bristol-Myers Squibb Company’s stock price has changed by -0.11% over the past week, -1.59% over the past month and +11.51% over the last year.
CrowdStrike Holdings, Inc. provides cloud-delivered protection across endpoints and cloud workloads, identity, and data. It offers threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management.
Based on the Crowdstrike Holdings Inc stock forecasts from 23 analysts, the average analyst target price for Crowdstrike Holdings Inc is USD 234.51 over the next 12 months. Crowdstrike Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Crowdstrike Holdings Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Crowdstrike Holdings Inc’s stock price was USD 168.97. Crowdstrike Holdings Inc’s stock price has changed by +1.29% over the past week, +2.52% over the past month and -18.35% over the last year.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe.
Based on the Affimed NV stock forecasts from 4 analysts, the average analyst target price for Affimed NV is USD 10.50 over the next 12 months. Affimed NV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Affimed NV is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Affimed NV’s stock price was USD 3.01. Affimed NV’s stock price has changed by -1.31% over the past week, -2.90% over the past month and -47.47% over the last year.
Coupa Software Incorporated provides cloud-based business spend management platform that connects its customers with suppliers worldwide. The company provides visibility into and control over how companies spend money, optimize supply chains, and manage liquidity, as well as enables businesses to achieve savings that drive profitability.
Based on the Coupa Software Incorporated stock forecasts from 18 analysts, the average analyst target price for Coupa Software Incorporated is USD 135.67 over the next 12 months. Coupa Software Incorporated’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Coupa Software Incorporated is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Coupa Software Incorporated’s stock price was USD 74.04. Coupa Software Incorporated’s stock price has changed by +7.63% over the past week, -2.60% over the past month and -68.72% over the last year.
PPG Stock Forecast & Price:
Based on the PPG Industries Inc stock forecasts from 16 analysts, the average analyst target price for PPG Industries Inc is USD 141.63 over the next 12 months. PPG Industries Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of PPG Industries Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, PPG Industries Inc’s stock price was USD 110.76. PPG Industries Inc’s stock price has changed by -7.04% over the past week, -13.54% over the past month and -27.06% over the last year.
Guidewire Software, Inc. provides software products for property and casualty insurers worldwide. The company offers Guidewire InsuranceSuite comprising Guidewire PolicyCenter, BillingCenter, and ClaimCenter applications.
Based on the Guidewire Software Inc stock forecasts from 7 analysts, the average analyst target price for Guidewire Software Inc is USD 103.27 over the next 12 months. Guidewire Software Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Guidewire Software Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Guidewire Software Inc’s stock price was USD 80.58. Guidewire Software Inc’s stock price has changed by +2.68% over the past week, +4.38% over the past month and -23.88% over the last year.
Digital Turbine, Inc., through its subsidiaries, provides media and mobile communication products and solutions for mobile operators, application advertisers, publishers, device original equipment manufacturers (OEMs), and other third parties. Its application media software platform that enables mobile operators and OEMs to control, manage, and monetize devices.
Based on the Digital Turbine Inc stock forecasts from 3 analysts, the average analyst target price for Digital Turbine Inc is USD 63.00 over the next 12 months. Digital Turbine Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Digital Turbine Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Digital Turbine Inc’s stock price was USD 19.68. Digital Turbine Inc’s stock price has changed by -16.79% over the past week, -37.82% over the past month and -70.93% over the last year.
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective.
Stock Target Advisor’s own stock analysis of ProShares Short Real Estate is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, ProShares Short Real Estate’s stock price was USD 20.28. ProShares Short Real Estate’s stock price has changed by +5.02% over the past week, +6.23% over the past month and +8.23% over the last year.
Based on the Owl Rock Capital Corp stock forecasts from 6 analysts, the average analyst target price for Owl Rock Capital Corp is USD 13.89 over the next 12 months. Owl Rock Capital Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Owl Rock Capital Corp is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Owl Rock Capital Corp’s stock price was USD 10.86. Owl Rock Capital Corp’s stock price has changed by +5.03% over the past week, -14.69% over the past month and -23.79% over the last year.
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol based networking and other products related to the communications and information technology industry in the Americas, Europe, the Middle East, Africa, the Asia Pacific, Japan, and China.
Based on the Cisco Systems Inc stock forecasts from 19 analysts, the average analyst target price for Cisco Systems Inc is USD 52.64 over the next 12 months. Cisco Systems Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Cisco Systems Inc is Bullish , which is based on 11 positive signals and 4 negative signals. At the last closing, Cisco Systems Inc’s stock price was USD 48.70. Cisco Systems Inc’s stock price has changed by +4.48% over the past week, +9.24% over the past month and -16.35% over the last year.
Based on the Pmv Pharmaceuticals Inc stock forecasts from 2 analysts, the average analyst target price for Pmv Pharmaceuticals Inc is USD 27.50 over the next 12 months. Pmv Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Pmv Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Pmv Pharmaceuticals Inc’s stock price was USD 13.56. Pmv Pharmaceuticals Inc’s stock price has changed by +2.65% over the past week, -12.12% over the past month and -58.01% over the last year.
Dynatrace, Inc. provides a software intelligence platform for dynamic multi-cloud environments. It operates Dynatrace, a software intelligence platform for running and optimizing the applications and services. The company's products include AppMon that works in various applications.
Based on the Dynatrace Inc stock forecasts from 15 analysts, the average analyst target price for Dynatrace Inc is USD 56.58 over the next 12 months. Dynatrace Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Dynatrace Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Dynatrace Inc’s stock price was USD 37.97. Dynatrace Inc’s stock price has changed by +7.29% over the past week, -4.84% over the past month and -22.76% over the last year.
Based on the PepGen Inc. stock forecasts from 5 analysts, the average analyst target price for PepGen Inc. is USD 22.60 over the next 12 months. PepGen Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of PepGen Inc. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, PepGen Inc.’s stock price was USD 11.19. PepGen Inc.’s stock price has changed by +24.33% over the past week, 0% over the past month and 0% over the last year.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders.
Based on the Athersys Inc stock forecasts from 2 analysts, the average analyst target price for Athersys Inc is USD 0.50 over the next 12 months. Athersys Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Athersys Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Athersys Inc’s stock price was USD 0.21. Athersys Inc’s stock price has changed by -67.08% over the past week, -61.09% over the past month and -87.11% over the last year.
Microsoft Corporation develops, licenses, and supports software, services, devices, and solutions worldwide. Its Productivity and Business Processes segment offers Office, Exchange, SharePoint, Microsoft Teams, Office 365 Security and Compliance.
Based on the Microsoft Corporation stock forecasts from 19 analysts, the average analyst target price for Microsoft Corporation is USD 346.94 over the next 12 months. Microsoft Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Microsoft Corporation is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Microsoft Corporation’s stock price was USD 247.65. Microsoft Corporation’s stock price has changed by -2.11% over the past week, -2.17% over the past month and -4.54% over the last year.
Terreno Realty Corporation and together with its subsidiaries, the "Company") acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. All square feet, acres, occupancy and number of properties disclosed in these condensed notes to the consolidated financial statements are unaudited.
Based on the Terreno Realty Corporation stock forecasts from 6 analysts, the average analyst target price for Terreno Realty Corporation is USD 77.14 over the next 12 months. Terreno Realty Corporation’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Terreno Realty Corporation is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Terreno Realty Corporation’s stock price was USD 55.50. Terreno Realty Corporation’s stock price has changed by -3.81% over the past week, -7.00% over the past month and -14.69% over the last year.
More Related Content
Similar to Rigel Pharmaceuticals Inc (RIGL) Stock Analysis
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 11 analysts, the average analyst target price for Moderna Inc is USD 184.76 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 121.08. Moderna Inc’s stock price has changed by -9.67% over the past week, -11.14% over the past month and -38.80% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 12 analysts, the average analyst target price for Moderna Inc is USD 195.35 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 140.00. Moderna Inc’s stock price has changed by -5.19% over the past week, +4.17% over the past month and -32.06% over the last year.
MRNA Stock Forecast & Price:
Based on the Moderna Inc stock forecast from 7 analysts, the average analyst target price for Moderna Inc is USD 147.44 over the next 12 months. Moderna Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Moderna Inc’s stock price was USD 123.42. Moderna Inc’s stock price has changed by +2.01% over the past week, -13.26% over the past month and -59.52% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Based on the Moderna Inc stock forecasts from 12 analysts, the average analyst target price for Moderna Inc is USD 195.35 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 143.40. Moderna Inc’s stock price has changed by +9.59% over the past week, +6.69% over the past month and -22.34% over the last year.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs).
Based on the IVERIC bio Inc stock forecasts from 9 analysts, the average analyst target price for IVERIC bio Inc is USD 23.22 over the next 12 months. IVERIC bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of IVERIC bio Inc is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, IVERIC bio Inc’s stock price was USD 11.25. IVERIC bio Inc’s stock price has changed by +8.91% over the past week, -9.35% over the past month and +70.45% over the last year.
Based on the Moderna Inc stock forecasts from 7 analysts, the average analyst target price for Moderna Inc is USD 147.44 over the next 12 months. Moderna Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Moderna Inc’s stock price was USD 118.07. Moderna Inc’s stock price has changed by -5.03% over the past week, -13.98% over the past month and -68.84% over the last year.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
Based on the Bristol-Myers Squibb Company stock forecasts from 9 analysts, the average analyst target price for Bristol-Myers Squibb Company is USD 73.91 over the next 12 months. Bristol-Myers Squibb Company’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bristol-Myers Squibb Company is Slightly Bearish, which is based on 6 positive signals and 9 negative signals. At the last closing, Bristol-Myers Squibb Company’s stock price was USD 75.09. Bristol-Myers Squibb Company’s stock price has changed by -0.11% over the past week, -1.59% over the past month and +11.51% over the last year.
CrowdStrike Holdings, Inc. provides cloud-delivered protection across endpoints and cloud workloads, identity, and data. It offers threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management.
Based on the Crowdstrike Holdings Inc stock forecasts from 23 analysts, the average analyst target price for Crowdstrike Holdings Inc is USD 234.51 over the next 12 months. Crowdstrike Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Crowdstrike Holdings Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Crowdstrike Holdings Inc’s stock price was USD 168.97. Crowdstrike Holdings Inc’s stock price has changed by +1.29% over the past week, +2.52% over the past month and -18.35% over the last year.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe.
Based on the Affimed NV stock forecasts from 4 analysts, the average analyst target price for Affimed NV is USD 10.50 over the next 12 months. Affimed NV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Affimed NV is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Affimed NV’s stock price was USD 3.01. Affimed NV’s stock price has changed by -1.31% over the past week, -2.90% over the past month and -47.47% over the last year.
Coupa Software Incorporated provides cloud-based business spend management platform that connects its customers with suppliers worldwide. The company provides visibility into and control over how companies spend money, optimize supply chains, and manage liquidity, as well as enables businesses to achieve savings that drive profitability.
Based on the Coupa Software Incorporated stock forecasts from 18 analysts, the average analyst target price for Coupa Software Incorporated is USD 135.67 over the next 12 months. Coupa Software Incorporated’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Coupa Software Incorporated is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Coupa Software Incorporated’s stock price was USD 74.04. Coupa Software Incorporated’s stock price has changed by +7.63% over the past week, -2.60% over the past month and -68.72% over the last year.
PPG Stock Forecast & Price:
Based on the PPG Industries Inc stock forecasts from 16 analysts, the average analyst target price for PPG Industries Inc is USD 141.63 over the next 12 months. PPG Industries Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of PPG Industries Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, PPG Industries Inc’s stock price was USD 110.76. PPG Industries Inc’s stock price has changed by -7.04% over the past week, -13.54% over the past month and -27.06% over the last year.
Guidewire Software, Inc. provides software products for property and casualty insurers worldwide. The company offers Guidewire InsuranceSuite comprising Guidewire PolicyCenter, BillingCenter, and ClaimCenter applications.
Based on the Guidewire Software Inc stock forecasts from 7 analysts, the average analyst target price for Guidewire Software Inc is USD 103.27 over the next 12 months. Guidewire Software Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Guidewire Software Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Guidewire Software Inc’s stock price was USD 80.58. Guidewire Software Inc’s stock price has changed by +2.68% over the past week, +4.38% over the past month and -23.88% over the last year.
Digital Turbine, Inc., through its subsidiaries, provides media and mobile communication products and solutions for mobile operators, application advertisers, publishers, device original equipment manufacturers (OEMs), and other third parties. Its application media software platform that enables mobile operators and OEMs to control, manage, and monetize devices.
Based on the Digital Turbine Inc stock forecasts from 3 analysts, the average analyst target price for Digital Turbine Inc is USD 63.00 over the next 12 months. Digital Turbine Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Digital Turbine Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Digital Turbine Inc’s stock price was USD 19.68. Digital Turbine Inc’s stock price has changed by -16.79% over the past week, -37.82% over the past month and -70.93% over the last year.
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective.
Stock Target Advisor’s own stock analysis of ProShares Short Real Estate is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, ProShares Short Real Estate’s stock price was USD 20.28. ProShares Short Real Estate’s stock price has changed by +5.02% over the past week, +6.23% over the past month and +8.23% over the last year.
Based on the Owl Rock Capital Corp stock forecasts from 6 analysts, the average analyst target price for Owl Rock Capital Corp is USD 13.89 over the next 12 months. Owl Rock Capital Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Owl Rock Capital Corp is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Owl Rock Capital Corp’s stock price was USD 10.86. Owl Rock Capital Corp’s stock price has changed by +5.03% over the past week, -14.69% over the past month and -23.79% over the last year.
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol based networking and other products related to the communications and information technology industry in the Americas, Europe, the Middle East, Africa, the Asia Pacific, Japan, and China.
Based on the Cisco Systems Inc stock forecasts from 19 analysts, the average analyst target price for Cisco Systems Inc is USD 52.64 over the next 12 months. Cisco Systems Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Cisco Systems Inc is Bullish , which is based on 11 positive signals and 4 negative signals. At the last closing, Cisco Systems Inc’s stock price was USD 48.70. Cisco Systems Inc’s stock price has changed by +4.48% over the past week, +9.24% over the past month and -16.35% over the last year.
Based on the Pmv Pharmaceuticals Inc stock forecasts from 2 analysts, the average analyst target price for Pmv Pharmaceuticals Inc is USD 27.50 over the next 12 months. Pmv Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Pmv Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Pmv Pharmaceuticals Inc’s stock price was USD 13.56. Pmv Pharmaceuticals Inc’s stock price has changed by +2.65% over the past week, -12.12% over the past month and -58.01% over the last year.
Dynatrace, Inc. provides a software intelligence platform for dynamic multi-cloud environments. It operates Dynatrace, a software intelligence platform for running and optimizing the applications and services. The company's products include AppMon that works in various applications.
Based on the Dynatrace Inc stock forecasts from 15 analysts, the average analyst target price for Dynatrace Inc is USD 56.58 over the next 12 months. Dynatrace Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Dynatrace Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Dynatrace Inc’s stock price was USD 37.97. Dynatrace Inc’s stock price has changed by +7.29% over the past week, -4.84% over the past month and -22.76% over the last year.
Based on the PepGen Inc. stock forecasts from 5 analysts, the average analyst target price for PepGen Inc. is USD 22.60 over the next 12 months. PepGen Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of PepGen Inc. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, PepGen Inc.’s stock price was USD 11.19. PepGen Inc.’s stock price has changed by +24.33% over the past week, 0% over the past month and 0% over the last year.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders.
Based on the Athersys Inc stock forecasts from 2 analysts, the average analyst target price for Athersys Inc is USD 0.50 over the next 12 months. Athersys Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Athersys Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Athersys Inc’s stock price was USD 0.21. Athersys Inc’s stock price has changed by -67.08% over the past week, -61.09% over the past month and -87.11% over the last year.
Similar to Rigel Pharmaceuticals Inc (RIGL) Stock Analysis (20)
Microsoft Corporation develops, licenses, and supports software, services, devices, and solutions worldwide. Its Productivity and Business Processes segment offers Office, Exchange, SharePoint, Microsoft Teams, Office 365 Security and Compliance.
Based on the Microsoft Corporation stock forecasts from 19 analysts, the average analyst target price for Microsoft Corporation is USD 346.94 over the next 12 months. Microsoft Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Microsoft Corporation is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Microsoft Corporation’s stock price was USD 247.65. Microsoft Corporation’s stock price has changed by -2.11% over the past week, -2.17% over the past month and -4.54% over the last year.
Terreno Realty Corporation and together with its subsidiaries, the "Company") acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. All square feet, acres, occupancy and number of properties disclosed in these condensed notes to the consolidated financial statements are unaudited.
Based on the Terreno Realty Corporation stock forecasts from 6 analysts, the average analyst target price for Terreno Realty Corporation is USD 77.14 over the next 12 months. Terreno Realty Corporation’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Terreno Realty Corporation is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Terreno Realty Corporation’s stock price was USD 55.50. Terreno Realty Corporation’s stock price has changed by -3.81% over the past week, -7.00% over the past month and -14.69% over the last year.
Core & Main, Inc. distributes water, wastewater, storm drainage, and fire protection products and related services to municipalities, private water companies, and professional contractors in the municipal, non-residential, and residential end markets in the United States.
Based on the Core & Main Inc stock forecasts from 7 analysts, the average analyst target price for Core & Main Inc is USD 29.18 over the next 12 months. Core & Main Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Core & Main Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Core & Main Inc’s stock price was USD 20.71. Core & Main Inc’s stock price has changed by -7.54% over the past week, -4.78% over the past month and 0% over the last year.
Stock Target Advisor’s own stock analysis of ProShares Metaverse ETF is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, ProShares Metaverse ETF’s stock price was USD 32.42. ProShares Metaverse ETF’s stock price has changed by -5.18% over the past week, -6.21% over the past month and +32,315.00% over the last year.
Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States.
Bragg Gaming Group Inc. operates as a technology and content supplier to the gaming industry worldwide.
Based on the Bragg Gaming Group Inc stock forecasts from 2 analysts, the average analyst target price for Bragg Gaming Group Inc is USD 15.33 over the next 12 months. Bragg Gaming Group Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bragg Gaming Group Inc is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, Bragg Gaming Group Inc’s stock price was USD 4.77. Bragg Gaming Group Inc’s stock price has changed by -19.15% over the past week, -0.42% over the past month and 0% over the last year.
Brookline Bancorp, Inc. operates as a bank holding company for the Brookline Bank that provide commercial, business, and retail banking services to corporate, municipal, and retail customers in the United States. Its deposit products include demand checking, NOW, money market, and savings accounts.
Based on the Brookline Bancorp Inc stock forecasts from 1 analysts, the average analyst target price for Brookline Bancorp Inc is USD 18.00 over the next 12 months. Brookline Bancorp Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Brookline Bancorp Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Brookline Bancorp Inc’s stock price was USD 13.13. Brookline Bancorp Inc’s stock price has changed by -3.46% over the past week, -8.63% over the past month and -20.52% over the last year.
Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. The company operates in two segments, Automotive, and Energy Generation and Storage.
Based on the Tesla Inc stock forecasts from 30 analysts, the average analyst target price for Tesla Inc is USD 921.57 over the next 12 months. Tesla Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Tesla Inc is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Tesla Inc’s stock price was USD 639.30. Tesla Inc’s stock price has changed by -11.10% over the past week, -11.74% over the past month and +5.69% over the last year.
Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. It also sells various related services. In addition, the company offers iPhone, a line of smartphones.
Based on the Apple Inc stock forecasts from 27 analysts, the average analyst target price for Apple Inc is USD 183.58 over the next 12 months. Apple Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apple Inc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Apple Inc’s stock price was USD 130.06. Apple Inc’s stock price has changed by -8.82% over the past week, -10.64% over the past month and -0.07% over the last year.
Five Below, Inc. operates as a specialty value retailer in the United States. It offers accessories, including socks, sunglasses, jewelry, scarves, gloves, hair accessories, athletic tops and bottoms, and t-shirts, as well as nail polishes, lip glosses, fragrances, and branded cosmetics.
Based on the Five Below Inc stock forecasts from 16 analysts, the average analyst target price for Five Below Inc is USD 197.68 over the next 12 months. Five Below Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Five Below Inc is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Five Below Inc’s stock price was USD 127.45. Five Below Inc’s stock price has changed by -2.60% over the past week, -8.37% over the past month and -32.82% over the last year.
The Lovesac Company designs, manufactures, and sells furniture. It offers sactionals, such as seats and sides; sacs, including foam beanbag chairs; and accessories comprising drink holders, footsac blankets, decorative pillows, fitted seat tables, and ottomans.
Based on the The Lovesac Company stock forecasts from 5 analysts, the average analyst target price for The Lovesac Company is USD 105.29 over the next 12 months. The Lovesac Company’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of The Lovesac Company is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, The Lovesac Company’s stock price was USD 31.82. The Lovesac Company’s stock price has changed by -12.46% over the past week, -15.12% over the past month and -65.18% over the last year.
Microsoft Corporation develops, licenses, and supports software, services, devices, and solutions worldwide. Its Productivity and Business Processes segment offers Office, Exchange, SharePoint, Microsoft Teams, Office 365 Security and Compliance, and Skype for Business.
Based on the Microsoft Corporation stock forecasts from 19 analysts, the average analyst target price for Microsoft Corporation is USD 347.83 over the next 12 months. Microsoft Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Microsoft Corporation is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Microsoft Corporation’s stock price was USD 252.99. Microsoft Corporation’s stock price has changed by -6.31% over the past week, -0.92% over the past month and -1.90% over the last year.
Ollie's Bargain Outlet Holdings, Inc. operates as a retailer of brand name merchandise. The company offers housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics; and other products.
Based on the Ollies Bargain Outlet Holdings Inc stock forecasts from 13 analysts, the average analyst target price for Ollies Bargain Outlet Holdings Inc is USD 55.65 over the next 12 months. Ollies Bargain Outlet Holdings Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Ollies Bargain Outlet Holdings Inc is Slightly Bearish, which is based on 7 positive signals and 9 negative signals. At the last closing, Ollies Bargain Outlet Holdings Inc’s stock price was USD 53.66. Ollies Bargain Outlet Holdings Inc’s stock price has changed by +13.23% over the past week, +21.95% over the past month and -38.62% over the last year.
Beam Global, a cleantech company, designs, develops, engineers, manufactures, and sells renewably energized products for electric vehicle (EV) charging infrastructure, outdoor media and branding, and energy security products.
Based on the Beam Global stock forecasts from 1 analysts, the average analyst target price for Beam Global is USD 25.00 over the next 12 months. Beam Global’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Beam Global is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Beam Global’s stock price was USD 19.26. Beam Global’s stock price has changed by +30.31% over the past week, +7.96% over the past month and -46.16% over the last year.
Block, Inc., together with its subsidiaries, creates tools that enables sellers to accept card payments and provides reporting and analytics, and next-day settlement. It provides hardware products, including Magstripe reader.
Based on the Block Inc stock forecasts from 32 analysts, the average analyst target price for Block Inc is USD 177.21 over the next 12 months. Block Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Block Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Block Inc’s stock price was USD 76.58. Block Inc’s stock price has changed by -12.42% over the past week, -8.68% over the past month and -63.57% over the last year.
Couchbase, Inc. provides a database for enterprise applications worldwide. Its database works in multiple configurations, ranging from cloud to multi- or hybrid-cloud to on-premise environments to the edge.
Based on the Couchbase Inc stock forecasts from 8 analysts, the average analyst target price for Couchbase Inc is USD 24.53 over the next 12 months. Couchbase Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Couchbase Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Couchbase Inc’s stock price was USD 16.00. Couchbase Inc’s stock price has changed by -0.56% over the past week, +12.36% over the past month and 0% over the last year.
Smartsheet Inc. provides cloud-based enterprise platform to plan, capture, manage, automate, and report on work for teams and organizations. The company offers Dashboards for real-time visibility into the status of work to align individuals, managers, and executives.
Based on the Smartsheet Inc stock forecasts from 13 analysts, the average analyst target price for Smartsheet Inc is USD 63.50 over the next 12 months. Smartsheet Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Smartsheet Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Smartsheet Inc’s stock price was USD 37.76. Smartsheet Inc’s stock price has changed by +4.22% over the past week, -13.51% over the past month and -40.00% over the last year.
Target Corporation operates as a general merchandise retailer in the United States. The company offers food assortments, including perishables, dry grocery, dairy, and frozen items.
Based on the Target Corporation stock forecasts from 25 analysts, the average analyst target price for Target Corporation is USD 216.11 over the next 12 months. Target Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Target Corporation is Very Bullish, which is based on 14 positive signals and 1 negative signals. At the last closing, Target Corporation’s stock price was USD 156.70. Target Corporation’s stock price has changed by +0.12% over the past week, -30.42% over the past month and -33.35% over the last year.
Based on the Joby Aviation stock forecasts from 5 analysts, the average analyst target price for Joby Aviation is USD 8.60 over the next 12 months. Joby Aviation’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Joby Aviation is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Joby Aviation’s stock price was USD 5.15. Joby Aviation’s stock price has changed by -12.71% over the past week, -3.38% over the past month and 0% over the last year.
Based on the Thoughtworks Holding Inc stock forecasts from 6 analysts, the average analyst target price for Thoughtworks Holding Inc is USD 27.50 over the next 12 months. Thoughtworks Holding Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Thoughtworks Holding Inc is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Thoughtworks Holding Inc’s stock price was USD 16.62. Thoughtworks Holding Inc’s stock price has changed by -3.99% over the past week, -4.97% over the past month and 0% over the last year.
Amazon.com, Inc. engages in the retail sale of consumer products and subscriptions in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It sells merchandise and content purchased for resale from third-party sellers through physical and online stores.
Based on the Amazon.com Inc stock forecasts from 30 analysts, the average analyst target price for Amazon.com Inc is USD 177.50 over the next 12 months. Amazon.com Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amazon.com Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Amazon.com Inc’s stock price was USD 123.00. Amazon.com Inc’s stock price has changed by -94.88% over the past week, -94.64% over the past month and -23.08% over the last year.
what is the best method to sell pi coins in 2024DOT TECH
The best way to sell your pi coins safely is trading with an exchange..but since pi is not launched in any exchange, and second option is through a VERIFIED pi merchant.
Who is a pi merchant?
A pi merchant is someone who buys pi coins from miners and pioneers and resell them to Investors looking forward to hold massive amounts before mainnet launch in 2026.
I will leave the telegram contact of my personal pi merchant to trade pi coins with.
@Pi_vendor_247
US Economic Outlook - Being Decided - M Capital Group August 2021.pdfpchutichetpong
The U.S. economy is continuing its impressive recovery from the COVID-19 pandemic and not slowing down despite re-occurring bumps. The U.S. savings rate reached its highest ever recorded level at 34% in April 2020 and Americans seem ready to spend. The sectors that had been hurt the most by the pandemic specifically reduced consumer spending, like retail, leisure, hospitality, and travel, are now experiencing massive growth in revenue and job openings.
Could this growth lead to a “Roaring Twenties”? As quickly as the U.S. economy contracted, experiencing a 9.1% drop in economic output relative to the business cycle in Q2 2020, the largest in recorded history, it has rebounded beyond expectations. This surprising growth seems to be fueled by the U.S. government’s aggressive fiscal and monetary policies, and an increase in consumer spending as mobility restrictions are lifted. Unemployment rates between June 2020 and June 2021 decreased by 5.2%, while the demand for labor is increasing, coupled with increasing wages to incentivize Americans to rejoin the labor force. Schools and businesses are expected to fully reopen soon. In parallel, vaccination rates across the country and the world continue to rise, with full vaccination rates of 50% and 14.8% respectively.
However, it is not completely smooth sailing from here. According to M Capital Group, the main risks that threaten the continued growth of the U.S. economy are inflation, unsettled trade relations, and another wave of Covid-19 mutations that could shut down the world again. Have we learned from the past year of COVID-19 and adapted our economy accordingly?
“In order for the U.S. economy to continue growing, whether there is another wave or not, the U.S. needs to focus on diversifying supply chains, supporting business investment, and maintaining consumer spending,” says Grace Feeley, a research analyst at M Capital Group.
While the economic indicators are positive, the risks are coming closer to manifesting and threatening such growth. The new variants spreading throughout the world, Delta, Lambda, and Gamma, are vaccine-resistant and muddy the predictions made about the economy and health of the country. These variants bring back the feeling of uncertainty that has wreaked havoc not only on the stock market but the mindset of people around the world. MCG provides unique insight on how to mitigate these risks to possibly ensure a bright economic future.
what is the future of Pi Network currency.DOT TECH
The future of the Pi cryptocurrency is uncertain, and its success will depend on several factors. Pi is a relatively new cryptocurrency that aims to be user-friendly and accessible to a wide audience. Here are a few key considerations for its future:
Message: @Pi_vendor_247 on telegram if u want to sell PI COINS.
1. Mainnet Launch: As of my last knowledge update in January 2022, Pi was still in the testnet phase. Its success will depend on a successful transition to a mainnet, where actual transactions can take place.
2. User Adoption: Pi's success will be closely tied to user adoption. The more users who join the network and actively participate, the stronger the ecosystem can become.
3. Utility and Use Cases: For a cryptocurrency to thrive, it must offer utility and practical use cases. The Pi team has talked about various applications, including peer-to-peer transactions, smart contracts, and more. The development and implementation of these features will be essential.
4. Regulatory Environment: The regulatory environment for cryptocurrencies is evolving globally. How Pi navigates and complies with regulations in various jurisdictions will significantly impact its future.
5. Technology Development: The Pi network must continue to develop and improve its technology, security, and scalability to compete with established cryptocurrencies.
6. Community Engagement: The Pi community plays a critical role in its future. Engaged users can help build trust and grow the network.
7. Monetization and Sustainability: The Pi team's monetization strategy, such as fees, partnerships, or other revenue sources, will affect its long-term sustainability.
It's essential to approach Pi or any new cryptocurrency with caution and conduct due diligence. Cryptocurrency investments involve risks, and potential rewards can be uncertain. The success and future of Pi will depend on the collective efforts of its team, community, and the broader cryptocurrency market dynamics. It's advisable to stay updated on Pi's development and follow any updates from the official Pi Network website or announcements from the team.
how can I sell pi coins after successfully completing KYCDOT TECH
Pi coins is not launched yet in any exchange 💱 this means it's not swappable, the current pi displaying on coin market cap is the iou version of pi. And you can learn all about that on my previous post.
RIGHT NOW THE ONLY WAY you can sell pi coins is through verified pi merchants. A pi merchant is someone who buys pi coins and resell them to exchanges and crypto whales. Looking forward to hold massive quantities of pi coins before the mainnet launch.
This is because pi network is not doing any pre-sale or ico offerings, the only way to get my coins is from buying from miners. So a merchant facilitates the transactions between the miners and these exchanges holding pi.
I and my friends has sold more than 6000 pi coins successfully with this method. I will be happy to share the contact of my personal pi merchant. The one i trade with, if you have your own merchant you can trade with them. For those who are new.
Message: @Pi_vendor_247 on telegram.
I wouldn't advise you selling all percentage of the pi coins. Leave at least a before so its a win win during open mainnet. Have a nice day pioneers ♥️
#kyc #mainnet #picoins #pi #sellpi #piwallet
#pinetwork
how can I sell my pi coins for cash in a pi APPDOT TECH
You can't sell your pi coins in the pi network app. because it is not listed yet on any exchange.
The only way you can sell is by trading your pi coins with an investor (a person looking forward to hold massive amounts of pi coins before mainnet launch) .
You don't need to meet the investor directly all the trades are done with a pi vendor/merchant (a person that buys the pi coins from miners and resell it to investors)
I Will leave The telegram contact of my personal pi vendor, if you are finding a legitimate one.
@Pi_vendor_247
#pi network
#pi coins
#money
The European Unemployment Puzzle: implications from population agingGRAPE
We study the link between the evolving age structure of the working population and unemployment. We build a large new Keynesian OLG model with a realistic age structure, labor market frictions, sticky prices, and aggregate shocks. Once calibrated to the European economy, we quantify the extent to which demographic changes over the last three decades have contributed to the decline of the unemployment rate. Our findings yield important implications for the future evolution of unemployment given the anticipated further aging of the working population in Europe. We also quantify the implications for optimal monetary policy: lowering inflation volatility becomes less costly in terms of GDP and unemployment volatility, which hints that optimal monetary policy may be more hawkish in an aging society. Finally, our results also propose a partial reversal of the European-US unemployment puzzle due to the fact that the share of young workers is expected to remain robust in the US.
Latino Buying Power - May 2024 Presentation for Latino CaucusDanay Escanaverino
Unlock the potential of Latino Buying Power with this in-depth SlideShare presentation. Explore how the Latino consumer market is transforming the American economy, driven by their significant buying power, entrepreneurial contributions, and growing influence across various sectors.
**Key Sections Covered:**
1. **Economic Impact:** Understand the profound economic impact of Latino consumers on the U.S. economy. Discover how their increasing purchasing power is fueling growth in key industries and contributing to national economic prosperity.
2. **Buying Power:** Dive into detailed analyses of Latino buying power, including its growth trends, key drivers, and projections for the future. Learn how this influential group’s spending habits are shaping market dynamics and creating opportunities for businesses.
3. **Entrepreneurial Contributions:** Explore the entrepreneurial spirit within the Latino community. Examine how Latino-owned businesses are thriving and contributing to job creation, innovation, and economic diversification.
4. **Workforce Statistics:** Gain insights into the role of Latino workers in the American labor market. Review statistics on employment rates, occupational distribution, and the economic contributions of Latino professionals across various industries.
5. **Media Consumption:** Understand the media consumption habits of Latino audiences. Discover their preferences for digital platforms, television, radio, and social media. Learn how these consumption patterns are influencing advertising strategies and media content.
6. **Education:** Examine the educational achievements and challenges within the Latino community. Review statistics on enrollment, graduation rates, and fields of study. Understand the implications of education on economic mobility and workforce readiness.
7. **Home Ownership:** Explore trends in Latino home ownership. Understand the factors driving home buying decisions, the challenges faced by Latino homeowners, and the impact of home ownership on community stability and economic growth.
This SlideShare provides valuable insights for marketers, business owners, policymakers, and anyone interested in the economic influence of the Latino community. By understanding the various facets of Latino buying power, you can effectively engage with this dynamic and growing market segment.
Equip yourself with the knowledge to leverage Latino buying power, tap into their entrepreneurial spirit, and connect with their unique cultural and consumer preferences. Drive your business success by embracing the economic potential of Latino consumers.
**Keywords:** Latino buying power, economic impact, entrepreneurial contributions, workforce statistics, media consumption, education, home ownership, Latino market, Hispanic buying power, Latino purchasing power.
how to sell pi coins in all Africa Countries.DOT TECH
Yes. You can sell your pi network for other cryptocurrencies like Bitcoin, usdt , Ethereum and other currencies And this is done easily with the help from a pi merchant.
What is a pi merchant ?
Since pi is not launched yet in any exchange. The only way you can sell right now is through merchants.
A verified Pi merchant is someone who buys pi network coins from miners and resell them to investors looking forward to hold massive quantities of pi coins before mainnet launch in 2026.
I will leave the telegram contact of my personal pi merchant to trade with.
@Pi_vendor_247
how to sell pi coins on Bitmart crypto exchangeDOT TECH
Yes. Pi network coins can be exchanged but not on bitmart exchange. Because pi network is still in the enclosed mainnet. The only way pioneers are able to trade pi coins is by reselling the pi coins to pi verified merchants.
A verified merchant is someone who buys pi network coins and resell it to exchanges looking forward to hold till mainnet launch.
I will leave the telegram contact of my personal pi merchant to trade with.
@Pi_vendor_247
What price will pi network be listed on exchangesDOT TECH
The rate at which pi will be listed is practically unknown. But due to speculations surrounding it the predicted rate is tends to be from 30$ — 50$.
So if you are interested in selling your pi network coins at a high rate tho. Or you can't wait till the mainnet launch in 2026. You can easily trade your pi coins with a merchant.
A merchant is someone who buys pi coins from miners and resell them to Investors looking forward to hold massive quantities till mainnet launch.
I will leave the telegram contact of my personal pi vendor to trade with.
@Pi_vendor_247
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...Vighnesh Shashtri
In India, financial inclusion remains a critical challenge, with a significant portion of the population still unbanked. Non-Banking Financial Companies (NBFCs) have emerged as key players in bridging this gap by providing financial services to those often overlooked by traditional banking institutions. This article delves into how NBFCs are fostering financial inclusion and empowering the unbanked.
when will pi network coin be available on crypto exchange.DOT TECH
There is no set date for when Pi coins will enter the market.
However, the developers are working hard to get them released as soon as possible.
Once they are available, users will be able to exchange other cryptocurrencies for Pi coins on designated exchanges.
But for now the only way to sell your pi coins is through verified pi vendor.
Here is the telegram contact of my personal pi vendor
@Pi_vendor_247
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
how to sell pi coins at high rate quickly.DOT TECH
Where can I sell my pi coins at a high rate.
Pi is not launched yet on any exchange. But one can easily sell his or her pi coins to investors who want to hold pi till mainnet launch.
This means crypto whales want to hold pi. And you can get a good rate for selling pi to them. I will leave the telegram contact of my personal pi vendor below.
A vendor is someone who buys from a miner and resell it to a holder or crypto whale.
Here is the telegram contact of my vendor:
@Pi_vendor_247
1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | NSD | Common Stock
Values as of 9th Jun, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Last Close
USD 0.72
Change
+0.02(+2.86%)
Market Cap
USD 0.12B
1 Yr Capital Gain
-82.78%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-82.78%
Earning Growth (5 yr)
74.12%
Average Target Price
2.58(+258.13% )
Average Analyst
Rating
Buy
Fundamental
Analysis
Slightly Bearish
Our view of the stock is Slightly Bearish with a score of 4.3 out of 10, where 0 is very bearish and 10 very bullish
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in
the long run.
What to not like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique
technology or market which can help it grow or get acquired in future.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering
to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and
management statements. Sometimes this is high because the company is trying to grow aggressively.
2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
RIGL
Rigel Pharmaceuticals Inc
-82.4% 0 -82.4%
QQQ
Invesco QQQ Trust
-11.1% +0.4% -10.7%
Company Overview
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer,
and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with
chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune
hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of
COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I
clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein
kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license
agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the
development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid
and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize
Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and
commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system
(non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San
Francisco, California.
3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.rigel.com
Address
1180 Veterans Boulevard, South San Francisco, CA, United States, 94080
Fiscal Year End
December
Employees
165
Technical Indicators
Value Value
Beta 1.50 52 Week High 4.62
Short Ratio 3.88 52 Week Low 0.69
Shorted Shares 6,689,236 200 Day Moving Average 2.87
Shorted Shares Previous Month 6,630,152 50 Day Moving Average 2.38
Shares Held By Insiders 62.30% Short Percentage 10.00%
Shares Held by Institutions 83.43 Dividend Yield N/A
4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -72.83% -43.0% 10% -18.3% 8%
Dividend Return N/A 1.0% N/A 1.0% N/A
Total Return -72.83% -43.0% 10% -17.9% 8%
Trailing 12 Months
Capital Gain -82.78% -66.5% 19% -22.1% 10%
Dividend Return N/A 1.5% N/A 2.3% N/A
Total Return -82.78% -66.5% 19% -21.1% 10%
Trailing 5 Years
Capital Gain -69.62% -58.4% 40% 3.6% 13%
Dividend Return N/A 13.9% N/A 10.9% N/A
Total Return -69.62% -55.9% 40% 14.1% 13%
Average Annual (5 Year Horizon)
Capital Gain 8.23% 2.9% 56% 2.3% 61%
Dividend Return N/A 9.4% N/A 1.8% N/A
Total Return 8.23% 3.9% 55% 4.2% 58%
Risk Return Profile
Volatility (Standard
Deviation)
50.77% 58.3% 57% 32.2% 29%
Risk Adjusted Return 16.21% N/A 58% 20.5% 46%
Market Capitalization 0.12B 0.13B 49% 0.32B 31%
5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 7.9 N/A 17.0 N/A
pbratio 50.9 1.8 3% 1.6 2%
pcfratio 20.5 -2.6 4% -0.1 15%
pfcfratio N/A 0.6 N/A 10.0 N/A
Management Effectiveness
retequity -199.44% -57.0% 14% 0.3% 6%
retinvcap -25.16% -54.2% 79% -0.6% 30%
retass -28.93% -26.2% 42% 0.1% 13%
debtequityratio 65.56% 20.7% 26% 32.1% 30%
Technical Ratios
yield N/A 1.9% N/A 2.6% N/A
sratio 3.88 4.81 57% 3.11 40%
spercent 4.56% 5.0% 55% 2.9% 38%
beta 1.50 1.41 44% 1.10 27%
6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Downgrades Citigroup Neutral USD 7 » USD 0.8 2022-06-09
Maintains B. Riley Neutral USD 4 » USD 1.25 2022-06-09
Target Down Jefferies Financial LLC Hold 2022-06-09
Maintains BMO Financial Outperform USD 7 » USD 3 2022-06-09
Downgrade Piper Sandler Overweight » Neutral USD 7 » USD 1 2022-06-08
Maintains HC Wainwright Buy USD 11 » USD 7 2022-06-08
Downgrade Cantor Fitzgerald Securities Overweight » Neutral USD 6 » USD 1 2022-06-08
Initiated by B. Riley Neutral USD 4 2022-03-23
Reiterated by BMO Financial Buy USD 8 2021-11-08
Reiterated by HC Wainwright Buy USD 11 2021-06-29
Target Raised by HC Wainwright Buy USD 8 » USD 11 2021-02-18
Downgrades JP Morgan & Company Neutral 2020-11-09
Target Raised by Citigroup Buy USD 7 » USD 8 2020-08-06
Target Lowered by JP Morgan & Company Overweight USD 7 » USD 6 2020-05-27
Lowers Target Cantor Fitzgerald Securities Overweight USD 7 » USD 5 2019-11-16
Maintains Cantor Fitzgerald Securities Overweight USD 7 » USD 5 2019-11-15
Assumes JP Morgan & Company Overweight USD 7 2019-09-26
Reiterated Cantor Fitzgerald Securities Overweight USD 9 2019-03-01
Set Price Target Cantor Fitzgerald Securities Buy USD 7 2019-02-28
Set Price Target HC Wainwright Buy USD 8 2019-01-11
Reiterates Cantor Fitzgerald Securities Buy USD 9 2019-01-08
Set Price Target HC Wainwright Buy USD 8 2018-11-07
Set Price Target HC Wainwright Buy USD 8 2018-10-05
Set Price Target Cantor Fitzgerald Securities Buy USD 9 2018-10-03
Reiterates JP Morgan & Company Overweight USD 7 2018-09-04
7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Annual Financial (USD)
8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Quarterly Financial (USD)
9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
RIGL:NSD (Rigel Pharmaceuticals Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 10th June, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc -14.84 (-5.4%) USD 70.22B
REGN Regeneron Pharmaceuticals Inc -32.28 (-5.3%) USD 66.76B
MRNA Moderna Inc -14.49 (-9.8%) USD 57.81B
ALXN Alexion Pharmaceuticals Inc N/A USD 40.34B
BNTX BioNTech SE -12.46 (-7.7%) USD 38.91B
RPRX Royalty Pharma plc -0.41 (-1.0%) USD 27.86B
SGEN Seagen Inc -2.54 (-1.8%) USD 26.56B
IMMU Immunomedics, Inc N/A USD 20.31B
GMAB Genmab AS -1.27 (-4.1%) USD 20.15B
BGNE BeiGene Ltd -11.41 (-7.0%) USD 18.09B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%